What's new in stroke prevention and treatment

Expert Review of Neurotherapeutics

Volumn 6, Issue 2, 2006, Pages 185-193

  Weimar, Christian ^a   Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Aspirin; Dipyridamole; Intracerebral hemorrhage; Prevention; Stroke; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DESMOTEPLASE; DIPYRIDAMOLE; EPROSARTAN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRENDIPINE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGE DISTRIBUTION; ANGIOPLASTY; ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; ENZYME BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOMA; HIGH RISK PATIENT; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; INTRACRANIAL PRESSURE; MIDDLE CEREBRAL ARTERY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECANALIZATION; REVIEW; SEX ROLE; STATISTICAL SIGNIFICANCE; STENOSIS; STENT; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT FAILURE; TREATMENT OUTCOME;

CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; EXPERT TESTIMONY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; META-ANALYSIS; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33645870435     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.2.185     Document Type: Review

References (59)

1. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304 (2005).
2. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses. Arch. Neurol. 57, 326-332 (2000).
3. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, 234S-264S (2004).
4. Fung TT, Stampfer MJ, Manson JE, Rexrode KM, Willett WC, Hu FB. Prospective study of major dietary patterns and stroke risk in women. Stroke 35, 2014-2019 (2004).
5. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up to date meta-analysis. Stroke 35, 2902-2909 (2004).
6. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology64, 817-820 (2005).
7. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284, 2901-2906 (2000).
8. Halliday A, Mansfield A, Marro J et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363, 1491-1502 (2004).
9. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 273, 1421-1428 (1995).
10. Hacke W, Donnan G, Fieschi C. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363, 768-774 (2004).
11. Wardlaw JM, Sandercock SP, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 34, 1437-1442 (2003).
12. Ribo M, Molina CA, Rovira A et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36, 602-606 (2005).
13. Rother J, Schellinger PD, Gass A et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 h. Stroke 33, 2438-2445 (2002).
14. Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36, 66-73 (2005).
15. Alexandrov AV, Molina CA, Grotta JC et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 351, 2170-2178 (2004).
16. Daffertshofer M, Gass A, Ringleb P et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischaemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a Phase II clinical trial. Stroke 36, 1441-1446 (2005).
17. Beletsky V, Nadareishvili Z, Lynch J, Shuaib A, Woolfenden A, Norris JW. Cervical arterial dissection: time for a therapeutic trial? Stroke 34, 2856-2860 (2003).
18. Georgiadis D, Lanczik O, Schwab S et al. IV thrombolysis in patients with acute stroke due to spontaneous carotid dissection. Neurology 64, 1612-1614 (2005).
19. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase 2 trial. Stroke 36, 880-890 (2005).
20. Wojner-Alexandrov AW, Garami Z, Chernyshev OY, Alexandrov AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 64, 1354-1357 (2005).
21. Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke 33, 497-501 (2002).
22. Dennis MS, Lewis SC, Warlow C. Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomised controlled trial. Lancet 365, 755-763 (2005).
23. Dennis MS, Lewis SC, Warlow C. Effect of timing and method of enterai tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet 365, 764-772 (2005).
24. Aslanyan S, Weir CJ, Johnston SC, Lees KR. Poststroke neurological improvement within 7 days is associated with subsequent deterioration. Stroke 35, 2165-2170 (2004).
25. Johnston SC LE, Hansen MD, Adams HP Jr. Early recovery after cerebral ischaemia risk of subsequent neurological deterioration. Ann. Neurol. 54, 439-444 (2003).
26. Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC. Neurologic worsening during the acute phase of ischemic stroke. Arch. Neurol. 62, 393-397 (2005).
27. Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352, 1305-1316 (2005).
28. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
29. Albers G, Diener HC, Frison L et al. Ximelagatran vs. warfarin for stroke prevention in patients with nonvavular atrial fibrillation. JAMA 293, 690-698 (2005).
30. Leonardi-Bee J, Bath PM, Bousser MG et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 36, 162-168 (2005).
31. Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996).
32. Wolf PA, D'Agostino B, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 22, 312-318 (1991).
33. Kernan WN, Viscoli CM, Brass LM et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischaemia and nondisabling ischemic stroke. Stroke 31, 456-462 (2000).
34. Sacco RL, Sivenius J, Diener HC. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch. Neurol. 62, 403-408 (2005).
35. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339 (1996).
36. Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin. Pharmacother. 6, 755-764 (2005).
37. Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 1, 19-26 (2005).
38. Diener H, Bogousslavsky J, Brass L et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 364, 331-334 (2004).
39. Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36, 1218-1226 (2005).
40. Yadav JS, Wholey MH, Kuntz RE et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. 351, 1493-1501 (2004).
41. Ringleb P, Kunze A, Allenberg J et al. The stent-supported percutaneous angioplasty of the carotid artery vs. endarterectomy trial (SPACE). Cerebrovasc. Dis. 18, 66-68 (2004).
42. Theiss W, Hermanek P, Mathias K et al. Pro-CAS: a prospective registry of carotid angioplasty and stenting. Stroke 35, 2134-2139 (2004).
43. Kastrup A, Groschel K, Schulz JB, Nagele T, Ernemann U. Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. Stroke 36, 787-791 (2005).
44. Hill MD, Shrive FM, Kennedy J, Feasby TE, Ghali WA. Simultaneous carotid endarterectomy and coronary artery bypass surgery in Canada. Neurology 64, 1435-1437 (2005).
45. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really 'shut the door?' A prospective study with transcranial Doppler. Stroke 35, 2140-2144 (2004).
46. Carota A, Berney A, Aybek S et al. A prospective study of predictors of poststroke depression. Neurology 64, 428-433 (2005).
47. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 36, 1098-1103 (2005).
48. Mendelow A, Gregson B, Fernandes H et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365, 387-397 (2005).
49. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated Factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. 352, 777-785 (2005).
50. Mayer SA, Brun NC, Broderick J et al. Safety and feasibility of recombinant Factor VIIa for acute intracerebral hemorrhage. Stroke 36, 74-79 (2005).
51. Radziszewska B, Hart RG, Wolf PA, D'Agostino RB Sr, Cutler JA. Clinical research in primary stroke prevention: needs, opportunities, and challenges. Neuroepidemiology 25, 91-104 (2005).
52. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
53. Felten RP, Ogden NR, Pena C, Provost MC, Schlosser MJ, Witten CM. The Food and Drug Administration medical device review process: clearance of a clot retriever for use in ischemic stroke. Stroke 36, 404-406 (2005).
54. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 254, 322-334 (2003).
55. ECASS-III: Placebo-controlled trial of alteplase (rt-PA) In acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 h after stroke onset. Stroke Trials Directory. www.strokecenter.org/trials/faq.aspx3.
56. Study of Desmoteplase in Acute Ischemic Stroke (DIAS-2). National Library of Medicine. www.clinicaltrials.gov/ct/show/NCT00111852?order=00111851 NLM Identifier: NCT00111852.
57. Abciximab in Emergent Stroke Treatment Trial (AbESTT) - II. Stroke Trials Directory. www.strokecenter.org/trials/trialDetail.aspx?tid=568.
58. PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes. ClinicalTrials.gov National Library of Medicine. www.clinicaltrials.gov/show/NCT00153062 NLM Identifier: NCT00153062.
59. PC Trial. Patent foramen ovale and cryptogenic embolism. Stroke Trials Directory. www.strokecenter.org/trials/TrialDetail.aspx?tid=475.